<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00550095</url>
  </required_header>
  <id_info>
    <org_study_id>CVAL489AEG03</org_study_id>
    <nct_id>NCT00550095</nct_id>
  </id_info>
  <brief_title>To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A 24 Week, Multi-centre, Open Label, Non Controlled Study to Assess the Efficacy of Valsartan in Reducing Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the efficacy of the different dosage forms of Valsartan[80,
      160, and 320 mg] in reducing microalbuminuria/proteinuria in hypertensive patients with type
      2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Albumin Creatinine Ratio (ACR) from baseline over a period of 24 weeks.</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent reduction of (BP) at 24 weeks compared to baseline level. Percent of patients whose BP is controlled at 24 weeks (&lt; 130/80)</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">509</enrollment>
  <condition>Microalbuminuria</condition>
  <condition>Proteinuria</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>valsartan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valsartan</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females aged 35 to 75.

          -  Type 2 diabetes mellitus (DM) patients coupled with hypertension [sitting systolic
             blood pressure (SSBP) 140-179 mm Hg and/or SDBP 90-109 mm Hg].

          -  Urinary albumin creatinine Ratio (UACR)) indicating microalbuminuria/proteinuria
             [30-1000 mg/g or 2.5-25 mg/mmol]

          -  Body mass index (BMI) &lt;40 kg/m2

          -  Patients who will sign an informed consent.

        Exclusion Criteria

          -  Type 1 DM

          -  All causes of secondary diabetes mellitus

          -  Women of childbearing potential who refuse to use contraception.

          -  Pregnant or lactating females.

          -  Severe hypertension [SSBP&gt; 180 mmHg, sitting diastolic blood pressure (SDBP) &gt; 110
             mmHg ]

          -  Patients who are on combo therapy to control BP

          -  Patients who are already on Valsartan.

          -  Hypersensitivity to Valsartan.

          -  Renal artery stenosis [ unilateral or bilateral]

          -  Patients taking Î² blockers, (Angiotensin Converting Enzyme Inhibitor (ACEI) or
             spironolactone

          -  Heart Failure

          -  History of myocardial infarction, Percutaneous Transluminal Coronary Angioplasty(PTCA)
             or cerebrovascular accident within the preceding 3 months.

          -  Creatinine levels &gt; 1.4 mg/dl [ 0.07mmol/l]. Liver enzymes &gt; 2 times Upper Limit of
             the Normal Range(ULN). Diabetic keto-acidosis (DKA) within the last 6 months. Presence
             of diabetic neuropathy or retinopathy. Diabetic foot complications. Presence of
             infection at time of screening. Hyperkalemia (serum K+ &gt; 5.5 mmol/L)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site ,</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3964</url>
    <description>Results for CVAL489AEG03 from the Novartis Clinical Trials website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2007</study_first_submitted>
  <study_first_submitted_qc>October 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2007</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microalbuminuria/proteinuria</keyword>
  <keyword>hypertensive patients with type 2 diabetes</keyword>
  <keyword>Valsartan</keyword>
  <keyword>microalbuminuria/proteinuria in hypertensive patients with type 2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
    <mesh_term>Albuminuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

